Rinsho Ketsueki
Online ISSN : 1882-0824
Print ISSN : 0485-1439
ISSN-L : 0485-1439
Case Reports
Complication of pernicious anemia during interferon-β treatment for type C chronic hepatitis
Hiroyoshi ICHIHARAShiro KOHYasutaka AOYAMATakeo KUMURATadanobu OHTAYoshio FURUKAWAYoshiki TERADATakahisa YAMANEMasayuki HINOAtsuko MUGITANI
Author information
JOURNAL RESTRICTED ACCESS

2012 Volume 53 Issue 3 Pages 352-356

Details
Abstract
A 62-year-old man with chronic hepatitis C underwent interferon (IFN)-β therapy. After treatment for a period comprising 29 months and 2 weeks, hematological results showed a decrease in white blood cell, hemoglobin, and platelet counts (WBC 2,300/μl, Hb 7.2g/dl, PLT 4.7×104l), and IFN therapy was stopped. Despite therapy discontinuation, the pancytopenia continued to progress with elevation of LDH (LDH 4,898IU/l), and the patient was admitted to our hospital with suspected hematological disease. The patient underwent clinical screening, and pernicious anemia caused by vitamin B12 deficiency was diagnosed. The anemia rapidly improved with vitamin B12 treatment. Interferon is the mainstay of treatment for patients with viral hepatitis. While the adverse effects of interferon therapy are widely recognized, only a few reports have documented pernicious anemia developing during IFN-therapy. We recommend that particular attention be paid to such clinical and laboratory conditions as megaloblastic anemia when administering IFN. We also recommend checking the vitamin B12 level, as a deficiency of this vitamin may lead to the development of megaloblastic anemia.
Content from these authors
© 2012 The Japanese Society of Hematology
Previous article Next article
feedback
Top